Clinical Trial

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Name: A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma — clinical trial record (NCT07533942)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-31

Trial Details

NCT Number	NCT07533942
Lead Sponsor	Jazz Pharmaceuticals Collaborators: Chimerix, Inc.
Conditions	Meningioma
Enrollment	30 participants
Start Date	2026-07-16
Primary Completion	2028-10-25 (estimated)
Study Completion	2031-10-16 (estimated)
Updated on ClinicalTrials.gov	2026-07-30